CIRM Funded Clinical Trials

Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa

Disease Area:
CIRM Grant:
CLIN2-11620 (Active)
Award Value:
Trial Sponsor:
Cedars-Sinai Medical Center
Trial Stage:
Phase 1
Trial Status:
Targeted Enrollment:
16 ID:


Retinitis pigmentosa is a blinding eye disease that affects approximately 150,000 individuals in the US and 1.5 million people around the world. It is caused by the destruction of light-sensing cells in the back of the eye known as photoreceptors.  This leads to gradual vision loss and eventually blindness.

For this trial, human neural progenitor cells (hNPCs) are transplanted to the back of the eye of retinitis pigmentosa patients. The goal is that the transplanted hNPCs will integrate and create a protective layer of cells that prevent destruction of the adjacent photoreceptors. 


This is a Phase 1 study.


To evaluate safety and preliminary efficacy.

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website